Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for Warfarin: The apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or Are unsuitable for vitamin K Antagonist Treatment (AVERROES) trial

Stroke

Volumn 43, Issue 12, 2012, Pages 3291-3297

  Flaker, Greg C ^a   Eikelboom, John W ^b   Shestakovska, Olga ^b   Connolly, Stuart J ^b   Kaatz, Scott ^c   Budaj, Andrzej ^d   Husted, Steen ^e   Yusuf, Salim ^b   Lip, Gregory Y H ^f   Hart, Robert G ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c HENRY FORD HOSPITAL   (United States)

^d Postgraduate Medical School ^*  (Poland)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apixaban; Atrial fibrillation; Clinical trial; Factor Xa inhibitor; Hemorrhage; Risk prediction

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; VITAMIN K; WARFARIN;

EID: 84870950721     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.664144     Document Type: Article

References (25)

1. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systemic review. Am J Med. 2010;123:638.e4-645.e4.
2. Albers GW, Sherman DG, Gress DR, Paulseth JE, Petersen P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol. 1991;30:511-518.
3. Hart RG, Pearce LA, Aguilar M. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
4. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice database. Heart. 2001;86:284-288.
5. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164:55-60.
6. Dewilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92:1064-1070.
7. Connolly S, Eikelboom J, Joyner C, Diener C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
8. Eikelboom JW, O'Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, et al. Rationale and design of AVERROES: apixaban versus acetyl-salicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159:348-353.
9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular fltration rate. Ann Intern Med. 2009;150:604-612.
10. Pisters R, Lane DA, Nieuwlaat R, deVos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010;138:1093-1100.
11. Lip G, Frison L, Halperin J, Lane D. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2011;57:173-180.
12. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage. J Am Coll Cardiol. 2011;58:395-401.
13. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130:1390-1396.
14. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized Controlled trial. Lancet. 2003;362:1691-1698.
15. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA. 2005;293:690-698.
16. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903-1912.
17. The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonist for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet. 2008;371:315-321.
18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
19. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824-829.
20. Hylek E, Evans-Molina C, Shea C, Henault L, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115: 2689-2696.
21. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
22. Patel M, Mahaffey K, Garg J, Guohua P, Singer D, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
23. Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific polyclonal anti-human tissue factor antibody. Thromb Res. 1990;59:421-437.
24. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108:1447-1452.
25. Eisert WG, Hauel N, Stangler J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30:1885-1889.